In the phase II IM103-100 study, kidney transplant recipients were first randomized to belatacept more-intensive-based (n = 74), belatacept less-intensive-based (n = 71), or cyclosporine-based (n = 73) immunosuppression. At 3-6 months posttransplant, belatacept-treated patients were re-randomized to receive belatacept every 4 weeks This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
| INTRODUCTION
Short-term outcomes in kidney transplant recipients have improved, with reductions in the incidence of early acute rejection, but there have been only modest improvements in long-term survival. 1 There are multiple causes for the lack of progress in long-term outcomes, including the adverse effects of calcineurin inhibitors on cardiovascular risk factors, which can lead to premature death with a functioning graft; 2,3 calcineurin inhibitor-associated nephrotoxicity; [4] [5] [6] and chronic antibody-mediated rejection. A calcineurin inhibitor-free immunosuppressive regimen could potentially provide improved efficacy, safety, and preservation of renal function.
Belatacept is a selective T cell co-stimulation blocker approved in the United States, European Union, and other countries for preventing organ rejection in adult kidney transplant recipients. 7, 8 Belatacept was evaluated as part of a calcineurin inhibitor-free immunosuppressive regimen in the phase II IM103-100 study, in which patients undergoing renal transplantation were randomized to receive 1 of 2 belataceptbased dosing regimens or cyclosporine (CsA)-based immunosuppression. 9 While the efficacy of belatacept was comparable with CsA, renal function was significantly better in belatacept-treated vs CsA-treated patients at 12 months posttransplant. 9 The present post hoc analysis compared outcomes at 10 years posttransplant in belatacept-treated and CsA-treated patients participating in IM103-100.
| METHODS

| Study design
The design of IM103-100 (NCT00035555) has been described. 9 Briefly, IM103-100 was a 12-month, open-label, phase II study of kidney transplant recipients aged ≥18 years. Study participants were recipients of a primary or repeat transplant from a living or deceased donor. Patients were first randomized to receive belatacept moreintensive (MI)-based, belatacept less-intensive (LI)-based, or CsAbased immunosuppression, hereafter referred to as the population at first randomization (see Figure 1 for dose schedule). The belatacept LI regimen used in this study differed from the subsequently approved regimen. 7, 8 Patients randomized to belatacept MI or belatacept LI were re-randomized at 6 months or 3 months posttransplant, respectively, to receive belatacept 5 mg/kg either every 4 weeks or every 8 weeks, hereafter referred to as the population at second randomization ( Figure 1) ; the belatacept 4-weekly and 8-weekly dosing schedules were unique to this study. Patients first randomized to CsA received CsA-based immunosuppression throughout the study.
All patients received basiliximab induction, mycophenolate mofetil, and corticosteroids. If approved by the treating physician, patients were eligible to continue the treatment to which they had been assigned at the second randomization beyond 12 months.
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This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. The institutional review board/ ethics committee at each site approved the study protocol. All patients provided written informed consent.
| Outcomes and statistics
This intent-to-treat post hoc analysis examined efficacy and safety in all evaluable patients at 10 years posttransplant. The evaluable population was composed of patients who were alive and observable at 10 years postrandomization or who had died or experienced graft loss by year 10.
Biopsy-proven acute rejection (BPAR) was defined as histologically confirmed acute rejection by the central pathologist, regardless of the reason for biopsy. The cumulative event rates for BPAR were calculated for each regimen using the Kaplan-Meier method and compared using a log-rank test. Hazard ratios (HRs) and 95% confidence intervals (CIs) were derived using Cox regression. Time to death or graft loss was determined using the Kaplan-Meier method and compared between regimens using a log-rank test.
Renal function was estimated using the 6- person-years of exposure to assigned treatment.
| RESULTS
| Population at first randomization
| Efficacy
Of the 218 patients enrolled, 74 were initially randomized to belatacept MI, 71 to belatacept LI, and 73 to CsA ( Figure 2 ). The cumulative event rate for BPAR from first randomization to year 10 was 22.8% for belatacept MI, 37.0% for belatacept LI, and 25.8% for CsA ( Figure 3A ). Table S1 . Kaplan-Meier estimated rate of death or graft loss at year 10 was 24.0%
for belatacept MI, 6.1% for belatacept LI, and 16.8% for CsA ( Figure 4A ). Tables S2 and S3 , respectively.
| Renal function
Estimated mean GFR was stable over 10 years for both belatacept- Table 1 . Four patients experienced posttransplant lymphoproliferative disorder (PTLD) by year 10 (belatacept MI, n = 3; belatacept LI, n = 0; CsA, n = 1). The 3 cases of PTLD in belatacept F I G U R E 3 Biopsy-proven acute rejection from randomization to year 10 in (A) the population at first randomization, (B) the population at second randomization, and (C) the population at second randomization stratified by belatacept dosing frequency. BPAR, biopsy-proven acute rejection; CI, confidence interval; CsA, cyclosporine; HR, hazard ratio; LI, less intensive; MI, more intensive 
| Subgroup analysis of the population at second randomization
| Efficacy
Between the first and second randomizations, 23 belatacept-treated patients discontinued the study, and 2 patients randomized to CsA did not receive treatment. Consequently, 62 belatacept-treated patients were subsequently randomized to receive belatacept every 4 weeks and 60 were subsequently randomized to receive belatacept every 8 weeks. Seventy-one CsA-treated patients continued with
CsA-based immunosuppression (Figure 2 ). The cumulative event rate
for BPAR from second randomization to year 10 was 11.1% for be- Table S4 .
In total, 21.0% ( 
| Renal function
Estimated mean GFR was stable over 10 years for both belatacept- CsA-based regimen (P < .001 for overall treatment effect) ( Figure 5B 
| Safety
Serious AEs occurred in 67.7% (42 of 62) of patients receiving be- Table S5 . CsA was statistically significant (HR 3.02; 95% CI 1.07-8.52; P = .037).
| DISCUSSION
In this post hoc analysis of the IM103-100 study, no statistically significant differences in the Kaplan-Meier cumulative event rates for BPAR were observed at 10 years posttransplant for the belatacept MI, belatacept LI, or CsA regimens overall. The comparable rates of acute rejection for belatacept-based vs CsA-based immunosuppression were preserved over 10 years: acute rejection rates in the belatacept treatment arms (6%-7%) were noninferior to that observed in the CsA treatment arm (8%) at 6 months posttransplant in IM103-100.
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Most acute rejection events in belatacept-treated patients occur within 6 months of treatment initiation. 10, 12, 13 In IM103-100, most BPAR events in the population at first randomization were reported by month 6 (28 of 41, 68.3%).
The efficacy and safety of belatacept have also been exam- Long-term use of belatacept was not associated with discernible nephrotoxicity in IM103-100; estimated mean GFR was significantly higher for belatacept MI-based and belatacept LI-based vs CsA-based The exposure (patient-years) of a patient was calculated from the randomization date to the event date, to the date of last follow-up, or to year 10, whichever was earliest. b The exposure (patient-years) of a patient was calculated from the randomization date to the event date, to the date of last dose of study medication plus 56 d, or to year 10, whichever was earliest.
T A B L E 1 Cumulative incidence rates of selected safety events adjusted per 100 person-years of treatment exposure in the population at first randomization immunosuppression at 10 years posttransplant. Further, renal func- Unlike BENEFIT and BENEFIT-EXT wherein maintenance doses of belatacept were only administered every 4 weeks, the dosefinding IM103-100 study analyzed outcomes following a second randomization of belatacept-treated patients to either every 4-week or every 8-week belatacept dosing. As observed in the population at first randomization, cumulative rates of BPAR in the population at second randomization did not differ statistically across treatment regimens at 10 years posttransplant, although rates of BPAR were 2-fold higher in patients administered belatacept every 8 weeks vs every 4 weeks. Among belatacept-treated patients in the population at second randomization, most BPAR events occurred by month 6 (13 of 18, 72.2%). In a further subgroup analysis in which study participants were stratified by both belatacept dosing regimen and frequency, the cumulative BPAR rate was greatest in the subset of patients who received belatacept LI every 8 weeks. From the available data, it is not possible to determine whether the increased rate of BPAR in the belatacept LI every 8-week treatment arm was attributable to differences in the timing of belatacept conversion and/or dosing frequency. However, conversion of some patients to 8-weekly administration could offer both logistical and practical advantages. A precision medicine study, Precision Medicine Offers Belatacept Monotherapy (PROBE; NCT02939365), will seek to convert patients to belatacept monotherapy. Following conversion to belatacept monotherapy, the dosing regimen in eligible patients-as determined via biomarker assessment-will be extended from every 4 weeks to every 8 weeks.
Time to death or graft loss was similar for belatacept 4-weekly, belatacept 8-weekly, and CsA. Renal function was significantly greater for both belatacept groups (4-weekly and 8-weekly) vs CsA.
Notably, estimated mean GFR at year 10 was similar for the belata- 
